Terms: = Prostate cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Prognosis
4 results:
1. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Vale CL; Fisher DJ; Godolphin PJ; Rydzewska LH; Boher JM; Burdett S; Chen YH; Clarke NW; Fizazi K; Gravis G; James ND; Liu G; Matheson D; Murphy L; Oldroyd RE; Parmar MKB; Rogozinska E; Sfumato P; Sweeney CJ; Sydes MR; Tombal B; White IR; Tierney JF;
Lancet Oncol; 2023 Jul; 24(7):783-797. PubMed ID: 37414011
[TBL] [Abstract] [Full Text] [Related]
2. A Novel fgfr3 Splice Variant Preferentially Expressed in African American prostate cancer Drives Aggressive Phenotypes and Docetaxel Resistance.
Olender J; Wang BD; Ching T; Garmire LX; Garofano K; Ji Y; Knox T; Latham P; Nguyen K; Rhim J; Lee NH
Mol Cancer Res; 2019 Oct; 17(10):2115-2125. PubMed ID: 31266816
[TBL] [Abstract] [Full Text] [Related]
3. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract] [Full Text] [Related]
4. Germline genetic variants in men with prostate cancer and one or more additional cancers.
PiliƩ PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract] [Full Text] [Related]